happy people working in lab
Oncology

Complete Molecular Solutions for Cancer Research and Oncology Testing

Key topics in cancer research and biomarker detection

From discovery to diagnostics: Tools for cancer research and oncology testing

From discovery to diagnostics, cancer research and oncology testing depend on understanding of how tumors arise, evolve and interact with their surrounding microenvironment. Researchers and clinicians need reliable ways to characterize these genetic and molecular changes, from early biomarker discovery to tests that can help guide patient care.

Our dedicated oncology workflows connect every step of this journey, from sample prep to molecular analysis and data interpretation. Whether you're working in basic cancer biology, translational research or clinical testing, our tools support applications such as liquid biopsy, multimodal sequencing and profiling tumor heterogeneity using single-cell RNA-seq, NGS, PCR and digital PCR (dPCR). For translational and clinical contexts, we also provide solid tumor and blood cancer testing, CDx partnering and clinical NGS interpretation.

Accelerate cancer discovery

Understanding cancer starts with uncovering the biological mechanisms that drive disease, from tumor-immune interactions in the tumor microenvironment to genetic, transcriptional and molecular heterogeneity within tumors. These findings form the basis for identifying and validating biomarkers that inform diagnosis, prognosis and treatment response. QIAGEN provides tools to study tumor biology, analyze gene expression and detect variants using technologies such as NGS, single-cell RNA-seq and digital PCR (dPCR), supporting research from early discovery through translational studies.

Biomarker detection and monitoring

We provide the tools you need to bring biomarkers from the lab into the clinic, whether you're working on discovery, validation or clinical testing. See how our technologies support applications such as minimal residual disease (MRD) detection, recurrence monitoring and assessment of treatment response.

Want to reduce the time to interpret clinical NGS tests?
Empower your analysis with QIAGEN Clinical Insight Interpret.
Learn more

Build your workflow

Stories from the bench

See how other scientists are approaching challenges in cancer research. Read about their experiences, thoughts and visions, and see where the field is heading.

"Instead of waiting months for the next scan, oncologists could monitor disease in near-real time… It's about transforming cancer care from reactive to proactive."

– Gopal Ramachandran, Co-founder and Chief Scientific Officer, Tracer Biotechnologies

Read the full story

"One of our top RNA biomarkers that we have identified in early cancer signature is not highly expressed. QIAcuity essentially gave us this 1000-fold sensitivity boost that we needed."

– Rastislav Horos, DVM, PhD, Chief Technology Officer, Hummingbird Diagnostics

Read the full story

"We are combining two different approaches, next generation sequencing and digital PCR, each of which will provide us with different types of information that will help us reach our ultimate goal."

– Mateus Nobrega Aoki, PhD, Public Health Technologist, Oswaldo Cruz Foundation

Read the full story

"Our collaboration with QIAGEN has been very important in our ability to provide accurate and current annotations for the genomic data that our tests produce."

– Dr. Martina Lefterova, MD, PhD, Vice President and Executive Laboratory Director, Guardant Health

Read the full story

Consortia and initiatives – we're working together

QIAGEN participates in numerous renowned international consortia, grant projects and initiatives that strive to improve global healthcare.  They extend and access networks and infrastructures – and stimulate exchange between all relevant stakeholders – from science, medicine and government. Our active role in consortia  and initiatives keeps QIAGEN at the forefront of scientific findings and developments.